Broad scientific aims that can be addressed through the consortium include:

Biomarkers of lung cancer risk Extensive pilot data strongly supports the use of biomarkers in lung cancer risk prediction models. Within Project 2 we will systematically evaluate a comprehensive panel of promising risk biomarkers using pre- diagnostic blood samples. This will result in a selected panel of biomarkers of lung cancer risk that will be incorporated in risk prediction models, and used to identify those subjects most likely to benefit from CT- screening.